Dipty Jain

Dipty Jain

Auto-generated profile, based on publicly available information

Dipty Jain

Department of Pediatrics Government Medical College and Hospital Nagpur India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2024 in Hematology-American Society Hematology Education Program
Verified
Journal Article
Closed access
KGKalpna Gupta
Kalpna Gupta
LKLakshmanan Krishnamurti
Lakshmanan Krishnamurti
DJDipty Jain
Dipty Jain
India, the most populous nation in the world, also has a high frequency of the sickle hemoglobin (HbS) allele globally. The Arab Indian HbS haplotype in India is characterized by a relatively high percentage of fetal Hb, with widely varying frequencies of α-thalassemia. Hence, sickle cell disease (SCD) in India was perceived to be mild. Advances in the past decade in screening and SCD management have revealed that the severity of SCD in India is comparable to many other parts of the world. Clinical features in India include vaso-occlusive crisis, acute chest syndrome, avascular necrosis, renal involvement, stroke, etc, at a relatively young age. Once a fatal disease of childhood, the majority of patients born with SCD are expected to survive into adulthood, largely because of improvements in comprehensive care programs including newborn screening, penicillin prophylaxis, transcranial Doppler, and hydroxyurea therapy. Several centers are performing hematopoietic stem cell transplants successfully for SCD. To address the urgent need to control and manage SCD in India's population, the Government of India launched the National Sickle Cell Anaemia Elimination Mission, with significant funding for large-scale measures to screen, treat, counsel, educate, and develop technologies and novel therapies and gene therapies.

1 June 2020 in Indian Journal of Medical Research
Verified
Journal Article
Open access
PDF file
IOIsaac Odame
Isaac Odame
DJDipty Jain
Dipty Jain
Indian J Med Res, Official publication of Indian Council of Medical Research,India

28 October 2024 in British Journal of Haematology
Verified
Journal Article
Open access
TSTulika Seth
Tulika Seth
SUShashank Udupi
Shashank Udupi
SJSuman Jain
Suman Jain
SBSeema Bhatwadekar
Seema Bhatwadekar
NMNandakumar Menon
Nandakumar Menon
DJDipty Jain
Dipty Jain
Summary: Sickle cell disease (SCD) with vaso‐occlusive pain crisis (VOC) significantly impacts patient well‐being and often results in extensive healthcare resource utilization. This study assessed the VOC burden, its management and its impact on patients' quality of life (QoL). A cross‐sectional observational study was conducted between November 2021 and June 2022, including 1000 SCD patients from high‐prevalence states in India. Data on demographics, clinical characteristics, VOC severity, management and QoL were collected. The study revealed that 33.5% of patients reported at least one VOC episode during the study period. In the year prior to their enrolment, 836 (83.60%) patients reported at least one VOC episode, with an equal proportion of 407/487 (83.6%) adults and 429/513 (83.6%) paediatric patients, reducing their QoL across all domains compared to patients without VOC. Of these, 469/1000 patients (46.9%) experienced ≥3 VOC episodes. Additionally, 764/1000 (76.40%) patients managed their VOCs at healthcare facilities, with 501/1000 (50.1%) requiring inpatient admissions. Further, 71.80% of patients received Hydroxyurea (HU) therapy. The study depicts the severity of the Arab–Indian haplotype in Indian SCD patients visiting healthcare settings based on high VOC burden. This highlights the urgent need for better management strategies and resource allocation for these patients.

27 August 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
ASAshish Satav
Ashish Satav
VDVibhawari S. Dani
Vibhawari S. Dani
JPJayashri S. Pendharkar
Jayashri S. Pendharkar
ASAshish Rambhau Satav
Ashish Rambhau Satav
DRDhananjay Raje
Dhananjay Raje
ESEric Simoes
Eric Simoes
Background: Severely underweight (SUW) children contribute significantly to under-five mortality and morbidity. There are WHO guidelines for the management of severe acute malnutrition but no specific guidelines for SUW management. Objective: The objectives were to achieve a recovery rate of 30% at 90 days of treatment for severe underweight (SUW) children aged 6–60 months, compare changes in weight-for-age Z (WAZ) scores, growth patterns, and case fatality rates between intervention and reference arms (RA), and reduce the prevalence of SUW in the intervention arm (IA). The target of a 30% recovery rate was achievable and significant based on our past research conducted in similar settings. Methods: Design: A prospective controlled community-based, longitudinal, two arms (IA, RA), intervention study with long follow-up was conducted between January 2011 and October 2023. Setting: Primary care for participants from 14 villages in rural Melghat, India. Participants: The study participants included SUW children aged 6–60 months and age-matched (±2 weeks) normal controls. The SAMMAN (Acronym for SAM-Management) intervention was comprised of local therapeutic food-micronutrient (LTF-MN) therapy for 90 days, intensive behavior change communication, infection treatment, and quarterly anthropometric records. SUW recovery, growth patterns, case fatality rate, prevalence at 90 days of therapy and at 60 months of age, and survival until early adolescence were assessed. ANCOVA analysis was used to obtain changes in Z-scores. Results: In the IA, the recovery rate was 36.8% at 90 days and 78.2% at 60 months of age. The mean difference in change in WAZ scores between the intervention arm and the reference arm was statistically significant (p < 0.0001). Growth patterns were similar between the two arms up to early adolescence. The SUW case fatality rate was significantly lower in the IA (0.9%) as compared to 4.62% in the RA at 60 months (p = 0.022). The reduction in SUW prevalence in intervention villages was higher than in the control villages (p < 0.001). The cost of management per SUW child was 3888 INR (47 USD) less than RUTF. Conclusion: The SAMMAN intervention is safe and cost-effective for significantly improving WAZ scores, sustainable, and hence replicable in resource-limited areas.

23 January 2026 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
RJRabindra Kumar Jena
Rabindra Kumar Jena
MMManoranjan Mahapatra
Manoranjan Mahapatra
TDTuphan Kanti Dolai
Tuphan Kanti Dolai
RKRakhee Kar
Rakhee Kar
MBMaitreyee Bhattacharyya
Maitreyee Bhattacharyya
BPBiswa Prakash Patri
Biswa Prakash Patri

8 July 2022 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
SMSushma Malik
Sushma Malik
DJDipty Jain
Dipty Jain
CBChandrakant M. Bokade
Chandrakant M. Bokade
SSShakira Savaskar
Shakira Savaskar
LDLaxmikant S. Deshmukh
Laxmikant S. Deshmukh
RGRahul K. Gajbhiye
Rahul K. Gajbhiye